Buy, Sell or Hold: Summit Therapeutics (SMMT-Q)

Home

Daily Stock Opinions and Ratings

Summit Therapeutics (SMMT-Q)

NASDAQ:SMMT

24.65

0.36 (1.48%) 1d

Nervous markets await Nvidia

Investor Insights

This summary was created by AI, based on 1 opinions in the last 12 months.

Summit Therapeutics (SMMT-Q) has garnered reviews that highlight significant concerns regarding its financial performance and overall stability as an investment. Experts unanimously point out that the company does not generate any profits, which raises red flags for potential investors. Furthermore, the stock is characterized as a risky speculation, indicating that while it may have potential for high rewards, the uncertainty and lack of profitability make it a gamble rather than a sound investment. Investors are advised to exercise caution given the inherent risks associated with such speculative stocks. The overall sentiment points towards a cautious approach, especially for those who may not have the appetite for high-risk investments.

Consensus

Negative

Valuation

Overvalued

Similar

Evoke, ECVT

DON'T BUY

Doesn't make money and is a risky spec.

Showing 1 to 1 of 1 entries

Summit Therapeutics(SMMT-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 1

Stockchase rating for Summit Therapeutics is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Summit Therapeutics(SMMT-Q) Frequently Asked Questions

What is Summit Therapeutics stock symbol?

Summit Therapeutics is a American stock, trading under the symbol SMMT-Q on the NASDAQ (SMMT). It is usually referred to as NASDAQ:SMMT or SMMT-Q

Is Summit Therapeutics a buy or a sell?

In the last year, 1 stock analyst published opinions about SMMT-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Summit Therapeutics.

Is Summit Therapeutics a good investment or a top pick?

Summit Therapeutics was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Summit Therapeutics.

Why is Summit Therapeutics stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Summit Therapeutics worth watching?

In the last year, there was no coverage of Summit Therapeutics published on Stockchase.

What is Summit Therapeutics stock price?

On 2025-05-08, Summit Therapeutics (SMMT-Q) stock closed at a price of $24.65.

Most Recent Experts

Daniel Straus

National Bank Financial

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Stan Wong

Private Wealth Management, ScotiaMcleod

Stockchase Insights

5i Research

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.